23:45 , Jul 18, 2019 |  BC Extra  |  Financial News

Kronos parlays diverse pipeline into $105M series A

The speed at which Kronos assembled a broad small molecule platform against hard-to-target hormone receptors, transcription factors and E3 ligases enabled it to raise a $105 million A round led by seed investors Vida Ventures...
14:14 , Mar 25, 2019 |  BioCentury  |  Emerging Company Profile

China Oncology Focus: funding combinations

China Oncology Focus aims to differentiate itself from other Chinese in-licensing plays by leveraging the diversity of its pipeline to develop in-house combination therapies, with its PD-L1 therapy as a backbone. The company is seeking...
21:20 , Nov 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; cancer In vitro , cell culture and mouse studies identified a CDK9 inhibitor that could help treat colorectal and other cancers. Screening of a natural product library followed by chemical synthesis and...
15:29 , Nov 8, 2018 |  BC Innovations  |  Translation in Brief

Solid plans for CDK9

A team led by Temple University scientists has shed light on a new epigenetic mechanism behind a known cancer target, cyclin dependent kinase 9 (CDK9), that may broaden the scope of CDK9 inhibitors to include...
19:37 , Sep 20, 2018 |  BC Innovations  |  Emerging Company Profile

Recalcitrant Targets

With a fresh take on small molecule microarray technology, Kronos Bio Inc. aims to identify small molecule inhibitors of oncology targets considered undruggable, starting with a splice variant of the androgen receptor expressed in metastatic...
22:36 , Apr 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
23:10 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; autoimmune disease

INDICATION: Solid tumors; Crohn’s disease; inflammatory bowel disease (IBD) In vitro , cell culture and mouse studies suggest inhibiting CDK9 and GSK3 could help treat cancer, Crohn’s disease and ulcerative colitis. Chemical synthesis and in...
23:08 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies suggest inhibiting CDK9 could help treat castration-resistant prostate cancer (CRPC) that is resistant to BET bromodomain protein inhibitors. In a human BET inhibitor-resistant CRPC cell line, siRNA targeting CDK9...
23:46 , Aug 17, 2017 |  BC Week In Review  |  Clinical News

Cyclacel reports Phase I data for CDK2/9 inhibitor in solid tumors

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) reported data from 24 heavily treated patients with advanced solid tumors in the dose-escalation part 1 of a Phase I trial showing that 8-288 mg/m 2 /day doses of CYC065 given...
16:06 , Jun 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Epithelial cancer; leukemia; lymphoma In vitro and cell culture studies suggest inhibiting hyperphosphorylation of BRD4 could help treat NUT midline carcinoma (NMC) and other cancers. In human NMC, leukemia and lymphoma cell lines, levels...